Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E17.83 EPS (ttm)2.05 Insider Own0.03% Shs Outstand5.53B Perf Week0.44%
Market Cap201.66B Forward P/E12.78 EPS next Y2.85 Insider Trans-8.74% Shs Float5.53B Perf Month-0.63%
Income11.84B PEG3.18 EPS next Q0.62 Inst Own74.70% Short Float0.86% Perf Quarter-15.39%
Sales53.66B P/S3.76 EPS this Y-11.90% Inst Trans0.07% Short Ratio2.00 Perf Half Y-7.51%
Book/sh10.71 P/B3.40 EPS next Y1.28% ROA7.90% Target Price41.45 Perf Year-17.14%
Cash/sh2.33 P/C15.62 EPS next 5Y5.60% ROE20.00% 52W Range33.97 - 46.47 Perf YTD-16.47%
Dividend1.44 P/FCF48.82 EPS past 5Y1.00% ROI10.20% 52W High-21.54% Beta0.65
Dividend %3.95% Quick Ratio1.20 Sales past 5Y0.80% Gross Margin80.10% 52W Low7.33% ATR0.52
Employees92400 Current Ratio1.50 Sales Q/Q-1.50% Oper. Margin23.30% RSI (14)57.17 Volatility1.03% 1.38%
OptionableYes Debt/Eq0.78 EPS Q/Q36.80% Profit Margin23.60% Rel Volume0.52 Prev Close36.46
ShortableYes LT Debt/Eq0.61 EarningsOct 29 BMO Payout62.80% Avg Volume23.93M Price36.46
Recom2.50 SMA201.49% SMA501.76% SMA200-9.77% Volume12,353,830 Change0.00%
Oct-17-19Resumed BofA/Merrill Neutral $37
Jul-30-19Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $40
Jul-30-19Downgrade BofA/Merrill Buy → Neutral
Jun-04-19Resumed Morgan Stanley Overweight $48
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
Oct-21-19 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
11:00AM  What's in Store for Healthcare ETFs in Q3 Earnings? Zacks
08:21AM  Opko and Pfizer announce positive results in late-stage trial of human growth hormone treatment MarketWatch
08:00AM  OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency GlobeNewswire
06:55AM  TIMELINE-Popular heartburn medicine Zantac pulled off store shelves Reuters
Oct-18-19 11:23AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial Zacks
10:21AM  Factors Setting the Tone for Novartis' (NVS) Q3 Earnings Zacks
Oct-17-19 04:00PM  Top Stock Reports for Johnson & Johnson, Boeing & Pfizer Zacks
10:54AM  Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings? Zacks
09:30AM  PFE vs. NVO: Which Stock Is the Better Value Option? Zacks
09:28AM  Fitbit stock gains after company announces biotech partnership MarketWatch
09:00AM  Fitbit's plan to beat Apple in personal health Yahoo Finance
Oct-16-19 04:28AM  Viagra Inventor Raises Funds to Test AI-Generated Treatments Bloomberg
Oct-15-19 03:37PM  Health savings accounts provide benefits, tax advantages Yahoo Finance Video
12:37PM  Top 4 Mutual Fund Holders of Pfizer Investopedia
Oct-14-19 05:45PM  Pfizer (PFE) Gains As Market Dips: What You Should Know Zacks
03:59PM  Johnson and Johnson Stock Still Significantly Undervalued InvestorPlace
10:15AM  The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo Zacks
10:14AM  Lilly Gets FDA Approval for New Oral Tablets for Migraine Zacks
09:14AM  Why cell therapies are cancer's next frontier American City Business Journals
07:00AM  Market Morning: Economists Say Spend More, Viagra For Leukemia, Aerospace Mergers Market Exclusive
02:00AM  ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology PR Newswire
Oct-12-19 04:45AM  Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis Business Wire
Oct-11-19 05:10PM  Startup with eye on fatty liver disease NASH lays out $70M IPO plan American City Business Journals
11:03AM  Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals Zacks
09:18AM  Trader Toolkit: Cash Flow Benzinga
Oct-10-19 10:34AM  J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector Zacks
Oct-09-19 11:22AM  Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook Zacks
11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
11:10AM  Nektar's Shares Drop on Rating Downgrade by Goldman Sachs Zacks
Oct-08-19 05:45PM  Pfizer (PFE) Stock Moves -1.1%: What You Should Know Zacks
04:12PM  Were Hedge Funds Right About Souring on Pfizer? Insider Monkey
01:29PM  5 Underperforming Guru Stocks GuruFocus.com
12:35PM  Is Pfizer (NYSE:PFE) A Risky Investment? Simply Wall St.
08:27AM  REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:00AM  REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report Reuters
Oct-07-19 04:13PM  How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume Investor's Business Daily
09:54AM  Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study Zacks
09:51AM  Zoetis Appoints Kristin Peck as New CEO, Alaix to Retire Zacks
08:06AM  Akcea Stocks Soars on Pfizer Licensing Agreement TheStreet.com
06:50AM  Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Oct-04-19 11:11AM  Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY Zacks
10:31AM  J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug Zacks
Oct-03-19 05:54PM  US Indexes Close Higher Thursday GuruFocus.com
04:16PM  Dow Jones Today: A Rebound With an Asterisk InvestorPlace
01:09PM  Here is the 8th Most Popular Stock Among Hedge Funds Insider Monkey
12:32PM  Pres. Trump to expand private Medicare Advantage program Yahoo Finance Video
11:22AM  Merck's Pediatric Filings for Dificid Get FDA's Priority Review Zacks
09:31AM  The Zacks Analyst Blog Highlights: Pfizer, DISH Network, Micron Technology, Walt Disney and C.H. Robinson Zacks
09:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Oct-02-19 06:11PM  TIMELINE-Popular heartburn medicine Zantac pulled off store shelves Reuters
02:22PM  Top Analyst Reports for Pfizer, DISH & Micron Zacks
10:00AM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
09:53AM  Novartis (NVS) Announces Data on Asthma Drugs & Kisqali Zacks
09:33AM  Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO American City Business Journals
Oct-01-19 06:56PM  As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets GuruFocus.com
10:10AM  Why the Earnings Surprise Streak Could Continue for Pfizer (PFE) Zacks
09:51AM  AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study Zacks
05:52AM  LabCentral gets state, private funds for new biomanufacturing lab space American City Business Journals
Sep-30-19 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
05:45PM  Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen Zacks
04:25PM  Pfizer, Walgreens, UnitedHealth, Dow, 3M Are 5 Worst Dow Jones Stocks This Year Investor's Business Daily
10:46AM  Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study Zacks
09:30AM  Company News For Sep 30, 2019 Zacks
07:58AM  California investor buys 67,000-square-foot facility in Durham American City Business Journals
02:30AM  Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer Business Wire
Sep-29-19 10:30AM  Novartis says Kisqali boosts survival in breast cancer patients Reuters
Sep-27-19 05:03PM  Mylan Misled Investors Over EpiPen Pricing Probe, SEC Says Bloomberg
04:17PM  Growth stocks vs. value stocks Yahoo Finance Video
11:37AM  Dow flat despite gains for Walgreens Boots, Pfizer shares MarketWatch
11:27AM  Nektar Stock Down on Disappointing Breast Cancer Study Data Zacks
10:01AM  Dow Jones Today: Stocks Turn Mixed, Consumer Spending Data Weak, Wells Fargo Gets A New CEO Investor's Business Daily
09:01AM  UPDATE 1-Pfizer veteran Ian Read to retire as executive chairman Reuters
09:00AM  Pfizer Inc. Awards Golden Tickets to Neutrolis and Mediar Therapeutics Business Wire
08:14AM  Ian Read to retire as Pfizer executive chairman Reuters
08:00AM  Ian Read to Retire as Executive Chairman of Pfizers Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman Business Wire
07:56AM  The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave Benzinga
07:01AM  Pfizer shares up 1.3% premarket after reporting positive results in second trial of dermatitis treatment MarketWatch
06:45AM  Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Business Wire
05:50AM  Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug TheStreet.com
Sep-26-19 04:18PM  Pfizer buys Durham facility as expansion plans continue to unfold American City Business Journals
Sep-25-19 06:22PM  Protalix Completes Enrollment in Third Fabry Disease Study Zacks
12:37AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
Sep-24-19 11:46AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
10:19AM  Pfizer Declares Fourth-Quarter 2019 Dividend Business Wire
09:10AM  Exact Sciences Gets FDA Nod for Label Expansion of Cologuard Zacks
08:00AM  Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019 Business Wire
07:40AM  European biotech firm BioNtech plans to raise nearly $304 mln in U.S. IPO Reuters
06:34AM  LabCentral co-founder issues call to action' to biotechs on drug pricing American City Business Journals
Sep-23-19 06:27PM  US Indexes Close Mostly Flat Monday GuruFocus.com
05:45PM  Pfizer (PFE) Dips More Than Broader Markets: What You Should Know Zacks
05:10PM  Getting technical on a Dow 30,000 call Yahoo Finance Video
01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
12:51PM  These 3 Long-Term Dividend Payers Offer a High Forward Yield GuruFocus.com
11:17AM  Dow flat despite losses for shares of Dow Inc., UnitedHealth MarketWatch
10:32AM  Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label Zacks
10:27AM  Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC Zacks
Sep-21-19 09:02AM  NFL legend Terry Bradshaw buys and sells $5 million planes the way some people flip houses MarketWatch
Sep-20-19 10:02AM  Walgreens Boots, Pfizer share gains contribute to Dow's nearly 75-point jump MarketWatch
08:41AM  Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates Zacks
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as Merck KGaA, Nektar Therapeutics, and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFIZER INC10% OwnerSep 17Buy18.0050,000900,0004,593,847Sep 19 04:19 PM
Gottlieb ScottDirectorAug 23Buy34.723,000104,1603,000Aug 26 09:27 AM
DAMELIO FRANK AExecutive Vice PresidentJul 02Sale44.09153,1846,753,385337,392Jul 03 04:06 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentJun 20Sale44.0030,0001,320,00080,094Jun 21 04:08 PM
PFIZER INC10% OwnerMay 13Buy17.0050,000850,0003,249,973May 14 07:34 AM
MACKENZIE ALEXANDER RExecutive Vice PresidentApr 01Sale42.8315,000642,503110,094Apr 02 03:05 PM
JOHNSON RADY AExecutive Vice PresidentMar 15Sale41.138,700357,83159,797Mar 18 06:37 PM
Dolsten MikaelPresident R&DMar 04Sale43.5249,0822,136,293289,126Mar 05 04:54 PM
ROGERS DAWNExecutive Vice PresidentMar 04Sale42.9815,002644,79814,920Mar 05 04:55 PM
READ IAN CExecutive ChairmanMar 04Sale43.2950,7882,198,4741,639,280Mar 06 04:03 PM
READ IAN CExecutive ChairmanMar 04Sale43.17530,07822,882,7021,109,202Mar 06 04:03 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale43.268,725377,444172,094Mar 06 03:29 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale43.1463,9982,760,698108,096Mar 06 03:29 PM
Dolsten MikaelPresident R&DMar 01Option Exercise31.34106,1913,328,057438,679Mar 05 04:54 PM
Dolsten MikaelPresident R&DMar 01Sale43.56100,4714,376,852338,208Mar 05 04:54 PM
ROGERS DAWNExecutive Vice PresidentFeb 27Option Exercise32.2319,297621,94245,049Mar 01 07:47 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Option Exercise32.2385,7632,764,141228,743Mar 01 07:47 PM
YOUNG JOHN DGroup PresidentFeb 27Option Exercise32.23154,3744,975,474441,923Mar 01 07:47 PM
GOETTLER MICHAELGroup PresidentFeb 27Option Exercise32.2330,017967,44848,652Mar 01 07:37 PM
Hwang AngelaGroup PresidentFeb 27Option Exercise32.2311,792380,05623,635Mar 01 07:37 PM
JOHNSON RADY AExecutive Vice PresidentFeb 27Option Exercise32.2330,017967,44881,341Mar 01 07:37 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 27Option Exercise32.2364,3222,073,098123,145Mar 01 07:37 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 27Option Exercise32.2381,4752,625,939416,278Mar 01 07:37 PM
BOURLA ALBERTChief Executive OfficerFeb 27Option Exercise32.2364,3222,073,098331,982Mar 01 07:29 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 27Option Exercise32.2325,729829,246121,743Mar 01 07:29 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 27Option Exercise32.23182,2475,873,821588,177Mar 01 07:29 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0343,724919,516312,403Feb 26 07:45 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0318,004378,62461,182Feb 26 07:45 PM
BOURLA ALBERTChief Executive OfficerFeb 23Option Exercise21.0336,008757,248191,438Feb 26 07:45 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.0387,4491,839,052388,024Feb 26 07:45 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03185,1853,894,441522,576Feb 26 07:45 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.0397,7372,055,409205,833Feb 26 07:46 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0343,724919,51683,781Feb 26 07:45 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 23Option Exercise21.0341,615875,163144,164Feb 26 07:10 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0330,864649,070115,139Feb 26 07:10 PM
ROGERS DAWNExecutive Vice PresidentFeb 23Option Exercise21.0319,290405,66937,638Feb 26 07:10 PM
GOETTLER MICHAELGroup PresidentFeb 23Option Exercise21.0319,290405,66931,507Feb 26 07:11 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 01Sale42.755,000213,75040,057Feb 01 07:21 PM
Dolsten MikaelPresident R&DJan 31Option Exercise29.78125,9683,751,425362,051Feb 01 07:28 PM
LANKLER DOUGLAS MExecutive Vice PresidentJan 30Sale41.1938,8001,598,07145,057Feb 01 07:21 PM
READ IAN CChairman & CEONov 02Option Exercise26.641,100,20129,312,5881,760,958Nov 06 03:46 PM